The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Catwith9lives
It's hard to predict a share price. Looks undervalued to me. Agreements with leading cell therapy companies in cutting edge technology etc.
I aim to have a core holding for the long term. It has stakes in the pipeline of those cell therapy companies but it is valued at much less than those companies which is odd. Anyway valuations can take some time to catch up and the trend is up.
I'm currently looking at Maxcyte. I understand they are planning a NASDAQ listing at some point. Any thoughts on comparable cell therapy company valuations in the US and where the SP goes from here? I think there is a trading update tomorrow.
Don't think we will see these levels again imo. Look at the valuations of cell therapy companies in the USA - in the Billions. Sorry not ramping just my personal view please do your own research. There was a very good research note I read a while ago that is worth people considering.
Twitter update:
Congratulations to our partner, @VorBioPharma, on closing $110 million in Series B financing to advance their lead program into clinical trials and expand their portfolio.
https://mobile.twitter.com/MaxCyte_info/status/1280507996657909763
https://www.dailymail.co.uk/money/investing/article-7069991/MIDAS-SHARE-TIPS-Medical-group-MaxCyte-finger-pulse.html
Thought it was worth pushing this article up again that Trojan found as new investors might find it difficult to see and it is a good summary of the investment case here imo.
This seems to me to be one of the best biotech investments available today at a very reasonable price.
It is actually generating millions in revenue which for a biotechnology company is rare. Some of this repeat revenue from the sale of consumables.
But the main interest for me is the milestones and royalties the company can take in other companies drug developments these are not all paid just on a successful phase 3 so the company is making money as the other drug development companies move along in their research and development and pay MXCT milestones and licence fees etc.
I had thought about investing in Crispr therapeutics and wish I had when it was in the low 60s when I was looking. But then I thought that I am invested here and MXCT has stakes in some of Crispr's drug development and also in the other leading cell therapy companies - if they are successful MXCT is successful. MXCT do not fund the drug development trials of the other companies they do so themselves! What better business model is there out there?
Then you have the Carma cancer side which should soon become self funding.
I believe the company is also looking at a future Nasdaq listing as well.
Just thought I'd share my thoughts and see what people think as well as it seems a little too quiet on this board - that can be a good thing as well. GLA and imo Dyor.
https://www.trinitydelta.org/wp-content/uploads/2020/05/MaxCyte-Outlook-200526.pdf
MaxCyte: entering the sweet spot
Cell therapies are expected to become a major new class of therapeutic agent; and MaxCyte’s unrivalled expertise with flow electroporation puts it right at the heart of it. The strategic decision a decade ago to invest in and develop this now key enabling technology is set to pay off. MaxCyte’s ExPERT equipment range, coupled with proven processing skills, has resulted in a stream of collaborative partnerships with cell therapies’ leading players. Potential pre-commercialisation milestones now exceed $800m. The proprietary CARMA clinical programme is also reaching a pivotal moment and is expected to become self-financing by end-2021. We have updated our model to reflect the progress achieved, and £23.6m raise, which results in a valuation of £260m, equivalent to 340p a share.
Commenting on the annual results, Doug Doerfler, CEO of MaxCyte, said: "2019 was a year of outstanding progress across all areas of our business. Our Life Sciences business continued to exhibit strong growth, reflecting MaxCyte's leadership as an enabler of next-generation cell-based therapies and resulting in a period of financial outperformance.
"Over the year we maintained progress with our lead CARMA candidate, MCY-M11, which is advancing through a Phase I clinical trial, demonstrating the feasibility of our one-day cell therapy manufacturing process. We remain fully committed to the MCY-M11 clinical development programme, though are prepared for an impact on timelines due to delays caused by COVID-19 restrictions. In March 2020, dosing in the 4(th) cohort commenced according to schedule and at the higher dosing level. I am really proud of this achievement and would like to thank everyone involved in the trial to date.
"With unprecedented restrictions in place due to COVID-19, we remain mindful of the potential impact on revenues through slowdowns in customer operations or delays in clinical trials. However, we remain confident that MaxCyte has a resilient business model underpinned by strong recurring revenues and prospects for continued growth.
"We have every reason to remain highly optimistic for the future. I believe we will continue to see long-term momentum in MaxCyte's business as a whole and, notwithstanding the COVID-19 situation, I look forward to updating the market with our continued positive progress."